Danaher (NYSE:DHR)‘s stock had its “buy” rating reiterated by analysts at Stifel Nicolaus in a research note issued on Friday. They presently have a $110.00 price objective on the conglomerate’s stock. Stifel Nicolaus’ price objective points to a potential upside of 9.39% from the company’s current price.
Several other research analysts also recently commented on the company. Robert W. Baird reissued a “buy” rating and issued a $99.00 price objective on shares of Danaher in a research note on Friday, December 15th. Citigroup increased their price objective on Danaher to $107.00 and gave the company a “buy” rating in a research note on Friday, December 15th. Zacks Investment Research raised Danaher from a “hold” rating to a “buy” rating and set a $97.00 price objective for the company in a research note on Thursday, October 5th. Cowen reissued a “buy” rating and issued a $90.00 price objective on shares of Danaher in a research note on Wednesday, October 4th. Finally, Royal Bank of Canada reissued a “hold” rating and issued a $96.00 price objective on shares of Danaher in a research note on Thursday, January 4th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $95.86.
Shares of Danaher (NYSE:DHR) traded up $0.82 during mid-day trading on Friday, hitting $100.56. The stock had a trading volume of 2,278,162 shares, compared to its average volume of 2,250,000. The company has a current ratio of 1.43, a quick ratio of 1.00 and a debt-to-equity ratio of 0.42. The firm has a market cap of $69,950.00, a P/E ratio of 29.93, a price-to-earnings-growth ratio of 2.16 and a beta of 1.03. Danaher has a twelve month low of $78.97 and a twelve month high of $100.88.
In other Danaher news, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of the firm’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $92.64, for a total value of $11,671,620.96. Following the completion of the sale, the chief executive officer now directly owns 271,737 shares of the company’s stock, valued at approximately $25,173,715.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Donald J. Ehrlich sold 10,578 shares of the firm’s stock in a transaction on Tuesday, October 24th. The stock was sold at an average price of $90.82, for a total value of $960,693.96. Following the completion of the sale, the director now directly owns 104,621 shares of the company’s stock, valued at $9,501,679.22. The disclosure for this sale can be found here. Insiders sold a total of 273,810 shares of company stock valued at $25,218,813 over the last ninety days. Corporate insiders own 12.20% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the business. GQG Partners LLC acquired a new stake in shares of Danaher in the 2nd quarter worth $101,000. Zions Bancorporation increased its stake in shares of Danaher by 118.3% in the 3rd quarter. Zions Bancorporation now owns 1,231 shares of the conglomerate’s stock worth $106,000 after acquiring an additional 667 shares during the last quarter. Patten Group Inc. increased its stake in shares of Danaher by 262.3% in the 3rd quarter. Patten Group Inc. now owns 4,830 shares of the conglomerate’s stock worth $114,000 after acquiring an additional 3,497 shares during the last quarter. Monetary Management Group Inc. grew its holdings in shares of Danaher by 10.7% during the 2nd quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock worth $131,000 after purchasing an additional 150 shares during the period. Finally, Acrospire Investment Management LLC grew its holdings in shares of Danaher by 185.5% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,693 shares of the conglomerate’s stock worth $143,000 after purchasing an additional 1,100 shares during the period. 76.11% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/19/stifel-nicolaus-reaffirms-buy-rating-for-danaher-dhr.html.
Danaher Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.